Current Report Filing (8-k)
July 27 2022 - 8:37AM
Edgar (US Regulatory)
0001690080
false
0001690080
2022-07-27
2022-07-27
0001690080
ATNF:CommonStockParValue0.0001PerShareMember
2022-07-27
2022-07-27
0001690080
ATNF:WarrantsToPurchaseSharesOfCommonStockMember
2022-07-27
2022-07-27
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION
13 OR 15(d) OF THE
SECURITIES EXCHANGE
ACT OF 1934
Date of Report (Date of
earliest event reported): July 27, 2022
180 LIFE SCIENCES
CORP.
(Exact Name of Registrant
as Specified in Charter)
Delaware |
|
001-38105 |
|
90-1890354 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
3000 El Camino Real, Bldg. 4, Suite
200
Palo
Alto, CA |
|
94306 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone
number, including area code: (650) 507-0669
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on
which registered |
Common
Stock, par value $0.0001 per share |
|
ATNF |
|
The
NASDAQ Stock Market LLC |
Warrants
to purchase shares of Common Stock |
|
ATNFW |
|
The
NASDAQ Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 7.01. Regulation FD Disclosure
On
July 27, 2022, 180 Life Sciences Corp. (the “Company”) issued a press release discussing that a team led by researchers
at University of Oxford have been awarded a grant from the National Institute for Health and Care Research (NIHR) in the U.K. to conduct
a feasibility trial to investigate anti-tumor necrosis factor (TNF) therapy. A copy of the press release is furnished hereto as Exhibit 99.1,
and incorporated by reference into this Item 7.01.
The
information in Item 7.01 of this Form 8-K and Exhibit 99.1 attached hereto, shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject
to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. The furnishing of this Report is not
intended to constitute a determination by the Company that the information is material or that the dissemination of the information is
required by Regulation FD.
The
press release furnished as Exhibit 99.1 to this Current Report on Form 8-K, contains forward-looking statements within
the safe harbor provisions under The Private Securities Litigation Reform Act of 1995, and, as such, may involve known and unknown risks,
uncertainties and assumptions. These forward-looking statements relate to the Company’s current expectations and are subject to
limitations and qualifications set forth in the press release, as well as in the Company’s other filings with the Securities and
Exchange Commission, including, without limitation, that actual events and/or results may differ materially from those projected in such
forward-looking statements. These statements also involve known and unknown risks, which may cause the results of the Company, its divisions
and concepts to be materially different than those expressed or implied in such statements. Accordingly, readers should not place undue
reliance on any forward-looking statements. Forward-looking statements may include comments as to the Company’s beliefs and expectations
as to future financial performance, events and trends affecting its business and are necessarily subject to uncertainties, many of which
are outside the Company’s control. More information on potential factors that could affect the Company’s financial results
is included from time to time in the “Forward-Looking Statements,” “Risk Factors” and “Management’s
Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s periodic and current
filings with the SEC, including the Form 10-Qs and Form 10-Ks, filed with the SEC and available at www.sec.gov. Forward-looking statements
speak only as of the date they are made. The Company undertakes no obligation to publicly update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: July 27, 2022
|
180 LIFE SCIENCES CORP. |
|
|
|
By: |
/s/ James N. Woody, M.D., Ph.D. |
|
|
Name: |
James N. Woody, M.D., Ph.D. |
|
|
Title: |
Chief Executive Officer |
2
180 Life Sciences (NASDAQ:ATNF)
Historical Stock Chart
From Mar 2024 to Apr 2024
180 Life Sciences (NASDAQ:ATNF)
Historical Stock Chart
From Apr 2023 to Apr 2024